Approval · Notice of Compliance 22022 · 2019
PROZINC: Notice of Compliance 22022
Issued March 29, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22022
- Date
- March 29, 2019
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Veterinary
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New species: dogs
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PROZINC | 02405202 | Marketed |
Medicinal ingredients
- HUMAN INSULIN (RECOMBINANT) 40 UNIT per ML